Perrigo Plc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Perrigo Plc (PRGO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Perrigo Plc vs Its Competitors
- TTM: Trailing 12-month revenue of 4,144M vs 400,608M combined for its competitors (1.0% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (-1.3% annualized vs trailing 12 months), vs holding steady (+1.1%) for its tracked peer group.
- Growth: Perrigo Plc generated -3.2% revenue growth year over year in Q2 2026, vs 5.1% for its competitors combined.
- Profitability: Its 7.3% net margin compares with 12.4% for the peer group.
- Scale: Perrigo Plc ranks #94 of 545 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Perrigo Plc accounted for 1.0% of combined revenue among its tracked peer group, down from 1.1% a year earlier.
- Peer differentiation: Revenue per employee of $0.51M compares with $0.75M for the peer group (0.7x).
- Structure: Perrigo Plc operates in the following segments: Self Care, Specialty Care, Infant Formula.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
PRGO Sales vs. its Competitors, Q2 2026
Perrigo Plc reported revenue contraction of 3.17 % year on year in Q2 2026, below its competitors' combined revenue growth of 5.05 %.
With a net margin of 7.27 %, Perrigo Plc reported lower profitability than its competitors (12.44 %).
Perrigo Plc generated 1.00 % of the combined sales of its peer group, down from 1.08 % a year earlier.
API endpoints for this dataset
Perrigo Plc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Perrigo Plc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Perrigo Plc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Perrigo Company Plc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (6) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (10) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (1) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Perrigo Plc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs -3.2% for Perrigo Plc. Perrigo Plc's share of combined industry revenue moved from 0.22% to 0.20%, a loss of 0.02 percentage points.
Perrigo Plc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Perrigo Company Plc | No | No | No | No |
| Competitors combined (21) | ||||
| High-Confidence Competitors (7) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 12.50 % (1 of 8) | 37.50 % (3 of 8) | 0.00 % (0 of 8) | 37.50 % (3 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
PRGO Stock Performance relative to its Competitors
PRGO Stock Performance relative to High-Confidence Competitors
PRGO Stock Performance relative to Similar-Size Competitors
PRGO Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Viatris Inc | 282.9% | Outperformed |
| 2 | Teva Pharmaceutical Industries Limited | 282.9% | Outperformed |
| 3 | Amneal Pharmaceuticals Inc | 282.9% | Outperformed |
| 4 | Johnson and Johnson | 282.9% | Outperformed |
| 5 | Therapeuticsmd Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Perrigo Plc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Perrigo Plc's Comment on Competition and Industry Peers
Publicly Traded Peers of Perrigo Company Plc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Perrigo Company Plc |
2,212.66 | 4,144.00 |
 Johnson and Johnson |
676,352.29 | 99,335.00 |
 Procter and Gamble Co |
398,150.88 | 87,922.00 |
 Novartis Ag |
317,785.25 | 56,674.00 |
 Gsk Plc |
207,208.61 | 43,093.89 |
 Abbott Laboratories |
191,605.90 | 46,585.00 |
| SUBTOTAL | 2,371,753.67 | 591,229.92 |
Sign in to see all competitors of Perrigo Company Plc.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Perrigo Company Plc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Perrigo Plc's Competitors Named by the Company
Competitive relationships identified from Perrigo Plc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Sanofi | Company report | 85% |
| Halozyme Therapeutics Inc | Company report | 85% |
| Scynexis Inc | Company report | 85% |
| 22nd Century Group inc | Company report | 85% |
| Prothena Corporation Public Limited Company | Company report | 85% |
| Dr. Reddy's Labs | Company report | 85% |
| Procter & Gamble | Company report | 85% |
| Aurobindo | Company report | 85% |
| Philips | Company report | 85% |
| Johnson & Johnson | Company report | 85% |
| Reckitt Benckiser | Company report | 85% |
| Bayer AG | Company report | 85% |
| PL Developments | Company report | 85% |
| Abbott Nutrition | Company report | 85% |
| LNK International, Inc. | Company report | 85% |
| Viatris Inc | Company report | 85% |
| Aim Immunotech Inc | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| Haleon Plc | Company report | 85% |
| Aptargroup inc | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Kenvue Inc | Company report | 85% |
| Teva Pharmaceutical Industries Limited | Company report | 85% |
| Taro Pharmaceutical Industries Ltd | Company report | 85% |
| Mallinckrodt Plc | Company report | 85% |
| Endo International Plc | Company report | 85% |
| Amphastar Pharmaceuticals Inc | Company report | 85% |
| Pfizer Inc | Company report | 85% |
| Lannett Company Inc | Company report | 85% |
| Amneal Pharmaceuticals Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Perrigo Plc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Perrigo Plc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Perrigo Company Plc | Self Care 61.98 % |
| Johnson and Johnson | Oncology 29.93 % |
| Procter and Gamble Co | Fabric & Home Care 35.25 % |
| Abbott Laboratories | Diabetes Care 16.79 % |
| Pfizer Inc | U.S. Commercial Division 58.35 % |
| Teva Pharmaceutical Industries Limited | United States 42.55 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Perrigo Company Plc.
Perrigo Plc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Perrigo Company Plc | 2,213 | 511,605 | -212,617 |
| Johnson and Johnson | 676,352 | 705,504 | 114,311 |
| Procter and Gamble Co | 398,151 | 845,404 | 154,750 |
| Novartis Ag | 317,785 | 752,973 | 185,566 |
| Gsk Plc | 207,209 | 169,660,977 | 32,662,867 |
| Abbott Laboratories | 191,606 | 405,087 | 47,174 |
| PEERS TOTAL | 2,369,541 | 752,349 | 106,264 |
Sign in to see all peers for Perrigo Company Plc.
Perrigo Plc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Perrigo Company Plc | United States 62.82 % |
| Johnson and Johnson | United States 58.90 % |
| Procter and Gamble Co | Non-US 52.05 % |
| Abbott Laboratories | Non-US 57.70 % |
| Pfizer Inc | United States 63.93 % |
| Bristol myers Squibb Company | United States 69.43 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Perrigo Company Plc.
Perrigo Plc's Position in Industry Market Structure
Market-capitalization share and concentration across all 495 companies in Perrigo Plc's industry classification, broader than the peer set above. Market cap in millions of $.Perrigo Plc ranks #94 of 495 companies by market capitalization in its industry, holding 0.04 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 875, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,210,070 | 20.69 % |
| 2 | Johnson and Johnson | 674,004 | 11.53 % |
| 3 | Beone Medicines Ltd | 612,622 | 10.48 % |
| 4 | Abbvie Inc | 515,910 | 8.82 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 94 | Perrigo Company Plc | 2,213 | 0.04 % |
Market cap and industry share for the rest of Perrigo Plc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-06.
Perrigo Plc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 89 | Newamsterdam Pharma Company N v | 2,316 | -50.39 % |
| 90 | Arcus Biosciences Inc | 2,305 | -9.54 % |
| 91 | Schrodinger Inc | 2,259 | 53.89 % |
| 92 | Trevi Therapeutics Inc | 2,244 | 24.53 % |
| 93 | Aurinia Pharmaceuticals Inc | 1,234 | 12.3% |
| 94 | Perrigo Company Plc | 2,213 | 3.71 % |
| 95 | Septerna Inc | 1,234 | 12.3% |
| 96 | Biohaven Ltd | 1,234 | 12.3% |
| 97 | Zymeworks Inc | 1,234 | 12.3% |
| 98 | Vera Therapeutics Inc | 1,234 | 12.3% |
| 99 | Immunome Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Perrigo Plc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-06. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Perrigo Plc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (444 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.33 % | 37.89 % (avg) | -37.6 pp |
| Operating Margin | -0.35 % | industry median | +0.3 pp |
| EBITDA Margin | -0.22 % | -6.23 % (avg) | +6.0 pp |
| Capital Intensity (Capex / Revenue) | 1.85 % | 7.58 % (avg) | -5.7 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Perrigo Plc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.6x | - |
| EV / EBITDA | - | 15.9x | - |
| P/B | 0.5x | 4.3x | -3.8x |
| Return on Equity | -0.56 % | industry aggregate | -16.91 % |
| Return on Invested Capital | -0.22 % | -9.83 % (avg) | 9.61 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Perrigo Plc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2016 | 2017 | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 5.67 % | -6.33 % | 0.37 % | -18.79 % | 7.56 % | 4.58 % | -6.06 % | -2.74 % |
| Operating Margin | -37.87 % | 12.09 % | 4.23 % | 9.92 % | 1.77 % | 3.26 % | 2.58 % | -27.21 % |
| Return on Invested Capital | -11.47 % | 3.61 % | 1.32 % | 2.81 % | 0.54 % | 1.05 % | 0.82 % | -9.02 % |
| P/E | - | 105.0x | 49.4x | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Perrigo Plc's Strategic Group Map
Perrigo Plc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Perrigo Plc's trailing-12-month revenue growth of -4.2% and operating margin of -0.3% compares with an average of -1.2% growth and -1.0% margin across its 8 closest peers by combined growth, margin and ROIC -- Perrigo Plc sits below that peer average on growth and above it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Perrigo Plc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Perrigo Plc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Perrigo Plc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 875 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 1.85 % vs industry average 7.58 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Perrigo Plc's dedicated Suppliers and Customers pages, not here.
Perrigo Plc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Perrigo Plc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Perrigo Plc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 16.9 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Perrigo Plc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Perrigo Company Plc | 0.10 | 2.57 | 1.15 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Procter and Gamble Co | 0.26 | 0.71 | 0.71 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Gsk Plc | 0.16 | 0.82 | 0.87 |
| Abbott Laboratories | 0.42 | 1.50 | 0.44 |
Sign in to see all peers for Perrigo Company Plc.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Perrigo Plc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Perrigo Company Plc | Q2 2026 | -3.2 % | - |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Procter and Gamble Co | Q3 2026 | +4.0 % | -1.0 % |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Gsk Plc | Q4 2025 | +7.5 % | +120.0 % |
| Abbott Laboratories | Q2 2026 | +13.0 % | -47.8 % |
| PEERS TOTAL | +4.5 % | +23.5 % |
Sign in to see all peers for Perrigo Company Plc.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Perrigo Plc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Perrigo Company Plc | Q2 2026 | +2.2 % | -25.5 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Procter and Gamble Co | Q3 2026 | +7.3 % | +13.8 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Gsk Plc | Q4 2025 | +7.2 % | -0.6 % |
| Abbott Laboratories | Q2 2026 | +9.7 % | -1.0 % |
Sign in to see all peers for Perrigo Company Plc.
Perrigo Plc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Perrigo Company Plc | - | - | - |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Procter and Gamble Co | 12.54% | 17.47% | 29.71% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Gsk Plc | 10.09% | 44.94% | 38.67% |
| Abbott Laboratories | 5.56% | 6.45% | 10.41% |
Sign in to see all peers for Perrigo Company Plc.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Perrigo Plc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Perrigo Company Plc | - | 0.53 |
| Johnson and Johnson | 41.79 | 6.81 |
| Procter and Gamble Co | 25.02 | 4.53 |
| Novartis Ag | 22.73 | 5.61 |
| Gsk Plc | 36.26 | 4.81 |
| Abbott Laboratories | 35.35 | 4.11 |
| PEERS AVERAGE | 29.21 | 4.01 |
Sign in to see all peers for Perrigo Company Plc.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.